In the five years since Canada legalized cannabis, the market has grown rapidly, with consumers now able to choose from a wide variety of strains and products. Among the most important purchasing criteria for many cannabis users is the level of THC, the psychoactive compound that produces the “high.”
However, product labels may be misleading, often significantly overstating the THC potency of the product. This has been, and continues to be, a growing problem in Ontario—a problem that undermines consumer trust and threatens the legitimacy of the cannabis industry itself.
Cannabis testing laboratories, producers, and regulators have all sounded the alarm over inflated THC levels. Independent tests by laboratories, including a study from McMaster University, have shown that actual THC concentrations in cannabis products sold by the Ontario Cannabis Store are frequently lower than advertised. This is more than a mere technical discrepancy; it reflects a broader issue of misrepresentation in an industry that was supposed to be transparent and regulated for the public good. As with any other consumer product, accuracy in labelling is essential not only for trust but also for health and safety.
The Roots of the Problem
The reasons behind this problem are varied but largely point to the pressures of a competitive market. The legal cannabis industry, like any other, is driven by consumer demand. In this case, the demand is increasingly for products with higher THC content. As a result, producers may feel incentivized to manipulate testing protocols or seek out laboratories willing to produce favourable test results.
Additionally, weak regulatory oversight compounds the issue. While Health Canada regulations set acceptable deviation limits for THC content, those rules cannot be ensured without enforcement. Without consistent standards for testing and reporting THC content, cannabis companies can exploit loopholes to artificially boost their product’s perceived strength.
Why Inflated THC Potency is a Problem
The effects of inflated THC labelling are wide-ranging. First and foremost, the misrepresentation of potency undermines the integrity of Ontario’s legal cannabis system. One of the primary goals of legalization was to move consumers away from the illicit market by offering a regulated, trustworthy alternative. If consumers can’t rely on the accuracy of labels in the legal market, they may lose faith in the system and return to other sources. The long-term consequence could be a serious blow to the credibility of an industry still fighting to gain widespread acceptance.
Moreover, inflated THC levels can lead to adverse health outcomes. Consumers who think they are purchasing a product with a higher THC content may either overuse weaker products in an attempt to achieve the desired effect or suffer unexpected consequences when using products that exceed their tolerance levels. Accurate labelling is essential for consumers to make informed decisions about dosage, effects, and risk, especially for medical cannabis patients who rely on precise THC levels to manage their conditions.
The issue also affects fair competition within the industry. Honest producers and testing labs that adhere to rigorous standards find themselves at a disadvantage, as they lose market share to competitors offering products with inflated THC claims.
The Path Forward
To address the issue of potency inflation, action is needed on multiple fronts. First, regulatory bodies must step up their oversight of cannabis testing and labelling. The Ontario Cannabis Store’s temporary testing program to address THC inflation is a good start, but a long-term solution must be found. Mandatory audits of testing laboratories and products should also be used to ensure compliance.
Independent testing to verify labs’ claims must be made permanent, and technology can make this an efficient process. Every stage of the legal cannabis supply chain is currently tracked electronically. By using advanced data-powered analytics and AI, regulatory bodies can spot potential products with inflated THC labels based on patterns in supply chain information. This can prioritize suspicious products for independent testing, helping ensure producers are incentivized to be honest.
The cost of inaction is high. Failure to address THC inflation can lead to costly fines of up to $1 million on producers from federal regulators. Health Canada and the federal government also need to do more to ensure that national quality control standards and regulations are being upheld.
Cannabis legalization was supposed to be about bringing this product out of the shadows and into a safe, regulated environment. It’s time for Ontario’s cannabis system to live up to that promise.
In the end, inflated THC labelling is more than just a technicality — it’s a serious breach of trust in an industry still establishing its place in the legal market.
David Albert is a principal with Wellington Dupont.
_______________________________________________________________________________
The views, opinions and positions expressed by all iPolitics columnists and contributors are the author’s alone. They do not inherently or expressly reflect the views, opinions and/or positions of iPolitics.